Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
Phase of Trial: Phase III
Latest Information Update: 29 Jun 2018
At a glance
- Drugs RP G28 (Primary)
- Indications Lactose intolerance
- Focus Registrational; Therapeutic Use
- Sponsors Ritter Pharmaceuticals
- 27 Jun 2018 According to a Ritter Pharmaceuticals media release,Status changed from not yet recruiting to recruiting.
- 27 Jun 2018 According to a Ritter Pharmaceuticals media release, first patient has been enrolled in this trial.
- 10 May 2018 Planned number of patients changed from 500 to 525.